| CL |
Report |
Organic sales growth (Q2) |
BEAT |
pred ~3.5% vs. cons ~3.0% |
MEDIUM |
| CL |
Report |
Base Business EPS (Q2) |
IN-LINE |
pred ~$0.97 vs. cons ~$0.96 |
MEDIUM |
| CL |
Report |
Base gross margin (Q2) |
MISS |
pred ~59.4% vs. cons ~59.9% |
MEDIUM |
| CL |
Guide |
FY26 organic sales growth |
UNCHANGED |
guide ~+1% to +4% vs. cons ~+3% (FY2026) |
MEDIUM |
| CL |
Guide |
FY26 base EPS growth |
UNCHANGED |
guide low-to-mid-single-digit (~+4%) vs. cons ~+4% (FY2026) |
MEDIUM |
| CL |
Guide |
FY26 gross margin outlook |
UNCHANGED |
guide ~'down' (~-30 to -50 bps) vs. cons ~-40 bps (FY2026) |
MEDIUM |
| CL |
Guide |
North America organic sales (sequential inflection) |
UNKNOWN |
pred ~-0.5% vs. cons ~0% (Q2 sequential from -2.2% Q1) |
LOW |
| CL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| CL |
Return |
5-day cumulative residual |
-2.0% (STABILIZE) |
EPS/organic likely in-line-to-modestly-above, but the gross-margin decline as commodity inflation peaks and a stretched ~24x multiple after an ~18% YTD run tilt the reaction to 'good but not good enough.' A held (not raised) EPS range with an explicitly lower margin line keeps out-period estimates drifting slightly lower, but CL's defensive quality, FX tailwind and dividend/buyback support limit further downside, so an initial negative move stabilizes rather than cascading. |
LOW |